Litcius/Paper detail

Systemic Inflammatory Score predicts Overall Survival in patients with Cervical Cancer

Mu Xu, Qibin Wu, Liangzhi Cai, Xiaoqi Sun, Xiaoyan Xie, Pengming Sun

2021Journal of Cancer21 citationsDOIOpen Access PDF

Abstract

Background: To evaluate the prognostic value of the systemic inflammatory score (SIS) in cervical cancer patients. Methods: A total of 264 patients with FIGO stage (2009) IB-IIA cervical cancer undergoing radical resection from January 2014 to December 2017 were recruited. The optimal cutoff values for inflammatory biomarkers were calculated by X-tile software. The prognostic factors were investigated using univariate and multivariate Cox analyses. Time-dependent receiver operating characteristic (time-ROC) analysis and the concordance index (C-index) were used to compare the prognostic impact of factors. Results: In total, 264 patients with cervical cancer were included in the study. The optimal cutoff value for lymphocyte-to-monocyte ratio (LMR) was 4.1. In multivariate analysis, FIGO stage, lymphovascular invasion, lymph node metastasis, preoperative serum albumin (Alb), and LMR were independent prognostic factors (P<0.05). Then, we combined preoperative Alb and LMR to establish the SIS. Multivariate analysis showed that the SIS was an independent factor that affected survival (P<0.05). When stratified by FIGO stage, significant differences in survival were also found for patients with different SISs (P<0.05). When the SIS and FIGO stage were combined, the time-ROC curve was superior to that of FIGO stage only. The C-index of the model combining the SIS and FIGO stage was 0.786 (95% CI 0.699-0.873), which was significantly higher than that of the model with FIGO stage only (0.676, 95% CI 0.570-0.782, P=0.0049).

Topics & Concepts

Cervical cancerMedicineInternal medicineOncologyOverall survivalCancerInflammatory Biomarkers in Disease PrognosisEndometrial and Cervical Cancer TreatmentsCancer Risks and Factors
Systemic Inflammatory Score predicts Overall Survival in patients with Cervical Cancer | Litcius